

## **Appendices**

Copy of registration forms used in the MoMaTEC trials;

#4 Inclusion form

#5 Follow-up form

#4 Inclusion form revised after introduction of FIGO 2009 classification

#5 Follow-up form revised after introduction of FIGO 2009 classification

# Study of prognostic markers in endometrial cancer curettage

Patient ID

## # 4 Registration– clinical data at primary treatment

Parity (no. of births):      Patients date of birth month      year

Menopausal status:      pre- (1)      peri- (2)      postmenopausal(3)

Primary treatment date for primary surgery:

hyst. with salpingoophorectomi (1)      palliative tumour reduction (2)      curettage only (3)

Lymphadenectomy:      yes(1)      no (2)      no. of lymph nodes removed

Additional treatment as a part of primary treatment:

no (0)      external radiation(1)      internal radiation(2)      chemotherapy(3)

hormonal treatment (4)      chemotherapy +radiation(5)      other(9)

Supplementary information: \_\_\_\_\_

Surgical FIGO stage (1988 criterias including histopathologic evaluation):

FIGO I (10)      FIGO IA (11)      FIGO IB (12)      FIGO IC (13)

FIGO II (20)      FIGO IIA (21)      FIGO IIB (22)

FIGO III (30)      FIGO IIIA (31)      FIGO IIIB (32)      FIGO IIIC (33)

FIGO IV (40)      FIGO IVA (41)      FIGO IVB (42)

Histopathologic results:

Histologic subtype:

endometrioid(1)      adenosq.(2)      clear cell(3)      serous pap.(4)      other(6)      hyperplasia(5)

Histologic grade:

high (grade 1, well differentiated)(1)      medium (grade 2) (2)      low (grade 3, poorly diff.) (3)

Lymph node metastases, histologically verified:

yes(1)      no (2)      Number of positive lymph nodes

\_\_\_\_\_  
Place, date

\_\_\_\_\_  
Signature physician

\_\_\_\_\_  
Name physician in print

Contact info: Professor Helga B Salvesen, e-post: [helga.salvesen@uib.no](mailto:helga.salvesen@uib.no)

Avdelingsingeniør Britt Edvardsen, e-post: [britt.edvardsen@helse-bergen.no](mailto:britt.edvardsen@helse-bergen.no)

Adresse:

Kvinneklinikken

Haukeland Universitetssykehus

Postadresse:

5021 Bergen

Norge

Telefon:

55974200

Telefax:

55974968

# Study of prognostic markers in endometrial cancer curettage

Patient ID

## # 5 Registration – clinical follow-up

### Recurrence:

Yes (1) no (2)

Date of recurrence: .

Location of recurrence: pelvic (1) distant metastases (2), where? \_\_\_\_\_

### Treatment of recurrence

No (0) external radiation (1) internal radiation (2) chemotherapy (3)

Hormonal treatment (4) chemotherapy + radiation (5) other (9)

Additional

information: \_\_\_\_\_

### Status at last follow-up:

Date for last follow-up information:

Alive and well (1)

Alive with active disease (2)

Dead from other causes (3)

Dead with but not due to active disease (4)

Dead from disease (5)

\_\_\_\_\_  
Place, date

\_\_\_\_\_  
Signature physician

\_\_\_\_\_  
Name physician in print

Contact info: Professor Helga B Salvesen, e-post: [helga.salvesen@uib.no](mailto:helga.salvesen@uib.no)

Avdelingsingeniør Britt Edvardsen, e-post: [britt.edvardsen@helse-bergen.no](mailto:britt.edvardsen@helse-bergen.no)

Adresse:

Kvinneklinikken

Haukeland Universitetssykehus

Postadresse:

5021 Bergen

Norge

Telefon:

55974200

Telefax:

55974968

# Study of prognostic markers in endometrial cancer curettage

Patient ID

## # 4 Registration – clinical data at primary treatment

Parity (no. of births):      Patient's date of birth month      year

Menopausal status:      pre- (1)      peri- (2)      postmenopausal(3)

Curettings histology:      low risk (1)\*      high risk (2)\*\*

\*low risk: benign, hyperplasia, endometrioid grade 1-2.

\*\*High risk: serous-papillary, clear cell, carcinosarcoma, endometrioid grade 3, undifferentiated

Primary treatment date of primary surgery:

hyst. with salpingoophorectomi (1)      palliative tumour reduction (2)      curettage only (3)

Lymphadenectomy:      pelvic(1)      paraaortic (2)      not performed (3) no.nodes removed

Additional treatment as a part of primary treatment:

none (0)      external radiation (+/- internal)(1)      internal radiation(2)      chemotherapy(3)

hormonal treatment (4)      chemotherapy +radiation(5)      other(9)

Supplementary information/ type of chemotherapy: \_\_\_\_\_

Surgical FIGO stage (2009 criteria including histopathologic evaluation):

FIGO I (10)      FIGO IA (11)      FIGO IB (12)      FIGO IC (13)      FIGO II (20)

FIGO III (30)      FIGO IIIA (31)      FIGO IIIB (32)      FIGO IIIC1 (33)      FIGO IIIC2 (34)

FIGO IV (40)      FIGO IVA (41)      FIGO IVB (42)

Histopathologic results:

Depth of myometrial infiltration:      <50% (1)      >50% (2)

Histologic subtype:      endometrioid(1)      adenosq.(2)      clear cell(3)      serous pap.(4)

carcinosarcoma(6)      hyperplasia(5)      undifferentiated/other (7)

Histologic grade:      grade 1, well differentiated(1)      grade 2 (2)      grade 3, poorly diff.(3)

Lymph node metastases histologically verified:      yes(1)      no (2)      not applicable (0)

Number of positive lymph nodes

\_\_\_\_\_  
Place, date

\_\_\_\_\_  
Signature physician

\_\_\_\_\_  
Name physician in print

Kontaktpersoner: Professor Helga B Salvesen, e-post: [helga.salvesen@uib.no](mailto:helga.salvesen@uib.no)

Avdelingsingeniør Britt Edvardsen, e-post: [britt.edvardsen@helse-bergen.no](mailto:britt.edvardsen@helse-bergen.no)

Adresse:

Kvinneklinikken

Haukeland Universitetssykehus

Postadresse:

5021 Bergen

Norge

Telefon:

55974200

Telefax:

55974968

# Study of prognostic markers in endometrial cancer curettings

Patient ID

Study ID

Initials

month/year  
of birth

# 5 *Registration– clinical follow-up*

Latest follow-up

Recurrence:

yes (1) no (2) progression/ non radically operated (3)

Date of recurrence/progression:

Localisation: vaginal vault (3) other pelvic (4) distant metastases (2)

If distant; where? \_\_\_\_\_

Confirmation by histology: yes (1) no (2)

Treatment of recurrence/ progression:

None (0) external radiation (+/- internal) (1) internal radiation (2)

chemotherapy (3) Hormonal treatment (4)

chemotherapy + radiation (5) other (9)

Additional information/type of chemotherapy:

---

Status at latest follow-up:

Date of latest follow-up:

alive, without recurrence of endometrial cancer (1)

alive, with known recurrence of endometrial cancer (2)

dead from other causes than endometrial cancer (3)

dead with, but not due to, endometrial cancer (4)

dead from endometrial cancer (5)

\_\_\_\_\_  
Place, date

\_\_\_\_\_  
Signature physician

\_\_\_\_\_  
Name physician in print

Contact info: Professor Helga B Salvesen, e-post: [helga.salvesen@uib.no](mailto:helga.salvesen@uib.no)

Avdelingsingeniør Britt Edvardsen, e-post: [britt.edvardsen@helse-bergen.no](mailto:britt.edvardsen@helse-bergen.no)

Adresse:

Kvinneklinikken

Haukeland Universitetssykehus

Postadresse:

5021 Bergen

Norge

Telefon:

55974200

Telefax:

55974968